StreetAlpha.app
Home › Stocks › CNSY

Cerenome, Inc. (CNSY)

$0.63
▼ −10.60%
LAST CLOSE · NOV 17

Plus Therapeutics develops diagnostic tests and targeted radiation treatments for cancers of the central nervous system. It last closed at $0.63 on Nov 17, down 10.60% on the day. The average 12-month price target from 2 analysts is $37.00 (+5770.2% from the last close), with a high of $43.00 and a low of $31.00.

AI Auto Pilots
Is CNSY in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$3.5M
−32.9% vs a year ago
Net income
−$30.3M
−859.5% margin
Free cash flow
−$28.7M
−813.5% margin
Operating margin
−832.6%
−$29.4M operating income
Valuation
Market cap
$6.2M
9.8M shares
P/E
–
Price to sales
1.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$879K
At Sep 30
Shareholder equity
−$923K
Shares outstanding
9.8M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $4.9M$4.9MFY2023FY2024: $5.8M$5.8MFY2024FY2025: $5.2M$5.2MFY2025

From CNSY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Last report
Nov 13
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated CNSY in the past 90 days, not enough for a consensus
Average 12-month target
$37.00
▲ 5770.2% upside

Based on 2 analysts who set a price target on CNSY in the past 90 days. The average target is $37.00, with a high of $43.00 and a low of $31.00, compared with the last close of $0.63.

Low $31.00Avg $37.00High $43.00
Blue marker: last close $0.63
Highest target$43.00
Average target$37.00
Lowest target$31.00
Latest rating changes
Lake StreetMaintained
Oct 1Buy$31
Ascendiant CapitalMaintained
Sep 11Buy$43
DateFirmActionRatingPrice target
Oct 1Lake StreetMaintainedBuy$31
Sep 11Ascendiant CapitalMaintainedBuy$43
Loading…

Whale Options Flow

90D

No whale options trades in CNSY in the last 90 days.

Loading…

See today’s whale options flow across the market →

CNSY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●8 buying vs 9 selling
  • ●Held by funds -0.0 pts
  • ●Funds holding +0
  • ▼Superinvestors: 0 added, 1 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding21210.0%
In funds' top 1000–
Held by funds6.4%6.4%−0.0 pts
New / increased5 / 318 / 0−55.6%
Reduced / sold out5 / 41 / 0+800.0%
Put/call ratio–––
SuperinvestorsKen GriffinSold out
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CNSY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CNSY is in one of them and how their past CNSY trades turned out.

CNSY in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CNSY in an article yet. Here's the latest on the wider market.

About Cerenome

Plus Therapeutics is a U.S. healthcare company based in Houston, Texas, that develops precision diagnostic tests and targeted radiopharmaceutical treatments for cancers of the central nervous system. Its CNSide Test is a laboratory developed test that identifies cancer cells spread to the brain and spinal fluid in patients with carcinomas and melanomas, and it is offered through national insurance agreements. Its lead drug candidate, rhenium (186Re) obisbemeda, is designed to deliver radiation directly into brain tumors such as recurrent glioblastoma and leptomeningeal metastases. The company is also developing a second radiotherapy candidate for liver cancers.

Headquarters
Houston, TX
Founded
1996